Last reviewed · How we verify
HR011408 injection; NovoRapid®
HR011408 injection; NovoRapid® is a Small molecule drug developed by Jiangsu HengRui Medicine Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | HR011408 injection; NovoRapid® |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Comparison of HR011408 and NovoRapid® in Subjects With Diabetics (PHASE1)
- The Pharmacokinetics and Pharmacodynamics Between HR011408 and NovoRapid® in Healthy Subject (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HR011408 injection; NovoRapid® CI brief — competitive landscape report
- HR011408 injection; NovoRapid® updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI
Frequently asked questions about HR011408 injection; NovoRapid®
What is HR011408 injection; NovoRapid®?
HR011408 injection; NovoRapid® is a Small molecule drug developed by Jiangsu HengRui Medicine Co., Ltd..
Who makes HR011408 injection; NovoRapid®?
HR011408 injection; NovoRapid® is developed by Jiangsu HengRui Medicine Co., Ltd. (see full Jiangsu HengRui Medicine Co., Ltd. pipeline at /company/jiangsu-hengrui-medicine-co-ltd).
What development phase is HR011408 injection; NovoRapid® in?
HR011408 injection; NovoRapid® is in Phase 1.